EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Considerations for veterinary scientific advice and marketing authorisations

IRISH MEDICINES BOARD

Presented by: Mary O'Grady
Irish Medicines Board

Veterinary scientific advice

Veterinary marketing authorisations

Scientific Advice applications in 2013



Pharmaceutical or immunological ?

Directive 2009/9/EC

- Title I

Requirements for veterinary medicinal products other than immunological veterinary medicinal products

- Title II

Requirements for immunological veterinary medicinal products

Pharmaceutical or immunological ?

- Stem cells
- Monoclonals
- Cytokines
- Bacteriophages
- 'Medical Device type' products
- Other biological molecules







Scientific Advice - Some issues

- Setting specifications
- Quality by Design
- Sterility
- Stability
- Other diverse topics

Setting specifications

VICH GL39: Test procedures and acceptance criteria for new veterinary drug substances and new medicinal products: chemical substances

- Universal tests
- Functionality related tests
- Impurities

Quality by Design

- ICH guidelines Q8-Q11
- Justification of the classification into critical and non-critical
- Risk assessment
  - Probability √
  - Impact √
  - Detection X
- Insufficient data
- Movement within a design space



Sterility

- Choice of sterilisation methods
- European Pharmacopoeia Monographs
- Follow decision trees EMEA/CVMP/065/99
    - For product and components
- Specific details of criteria for acceptance/rejection
- Equipment at production site not a justification

Stability

- Bracketing and Matrixing VICH GL 45
- Use of supporting data from similar products
- Stability indicating tests
- Accelerated studies for biologicals VICH GL17

Other issues

- Generics – data required to demonstrate pharmaceutical equivalence of products
- Quality of atypical active substances
- Child resistant closures
- Viral safety strategy
- TSE

General Advice

- Include sufficient information in the data package
  - Brief synopsis of the product and its stage of development
  - Background to the issue
  - Question to be answered must be clearly stated
- Review Ph. Eur. monographs and human guidelines
- Quote relevant guidelines
- Justify any omissions
- Do not omit the obvious

Veterinary marketing authorisations

- Development Pharmaceutics
- Manufacturing process/validation
- Active substance
- Specifications
- Specific dosage forms
  - Tablets
  - Parenteral preparations
  - Single dose spot on products

Use the Development Pharmaceutics Section

- To define the target product profile
- To identify critical quality attributes
- To determine quality attributes of the starting materials
- To aid the selection of an appropriate manufacturing process
- To identify a control strategy

Manufacturing process/validation

New process validation guideline – effective August 2014

EMA/CHMP/CVMP/QWP/70278/2012-Rev 1

'Guideline on process validation for finished products -information and data to be provided in regulatory submissions'

- Traditional process validation
- Continuous process verification
- Standard vs Non-standard processes

Active substance

- Starting materials
- GMP declarations
- Use of CEP's



Specifications

Specifications should:

- assure suitability for intended purpose
- assure animal safety
- reflect state of knowledge/development
- reflect capability of technology & process

As development proceeds, specifications should evolve.

Specifications

Specifications should be based upon the total database of relevant development information.

Development data should guide:

- Selection of tests included in specification
- Justification for not including certain tests
- Appropriateness of analytical procedure
- Justification of acceptance criteria

Specifications – Impurities

- Consider likely impurities present
- Determine content of each known impurity
- Identify and specify specifically toxic impurities
- Any unidentified impurities above ID threshold
- Qualification of impurities
- Acceptance criterion = Qualified level
- Any increase in impurity

Tablets – common issues

- Particle size
- Subdivision of tablets (halves/quarters)
- Shelf-life of half tablets
- Uniformity of dosage units
- Use of the term “chewable”
- Use of the term “flavoured”

Parenteral preparations – common issues

- Preservative efficacy testing
- In-use shelf life
- Self-sealing/fragmentation

Spot on Products – common issues

EMEA/CVMP/QWP/544461/2007 "Guideline on the Quality Aspects of <u>Single</u> Dose Veterinary Spot-On Products"

- Determine the residual volume of product in the pipette after the expression of the dose. This information should then be used to specify fill volume limits during the manufacturing process
- Express assay in terms of the quantity by mass of the active substance in a container of average delivered mass or volume. Limits of 95 – 105 % of the declared content should be applied to this parameter.
- Uniformity of dosage units (Ph. Eur. 2.9.40)

Familiarise yourself with



Thank you for your attention!